Training and Resources
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
KEYTRUDA® (pembrolizumab) plus KISPLYX® (lenvatinib) in advanced Renal Cell Carcinoma (aRCC)
KEYTRUDA® (pembrolizumab) plus KISPLYX® (lenvatinib) CLEAR trial slide deck
For full information about KEYTRUDA and KISPLYX adverse events, please refer to each product’s individual SmPC
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Your guide to recognising and managing KEYTRUDA® (pembrolizumab) plus KISPLYX® (lenvatinib) adverse events in aRCC
For full information about KEYTRUDA and KISPLYX adverse events, please refer to each product’s individual SmPC
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
HCP Resources
Patient assets
To order printed versions of these diaries to your place of work, please contact msdukoncology@msd.com.
KEYTRUDA® (pembrolizumab) in combination with KISPLYX® (lenvatinib) patient booklet and diary
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Please be aware you should not direct your patient to this website. You should download this diary on their behalf and share it with them as appropriate.
For more information about KEYTRUDA + KISPLYX in aRCC:
Supporting documentation
KEYTRUDA Prescribing Information for Great Britain & Northern Ireland
KISPLYX Prescribing information for Great Britain & Northern Ireland
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
